Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1651 to 1660 of 2580 total matches.

Over-the-counter (OTC) Cough Remedies

   
The Medical Letter on Drugs and Therapeutics • Mar 19, 2001  (Issue 1100)
. AND INTERNATIONAL COPYRIGHT LAWS 23 SOME OVER-THE-COUNTER COUGH REMEDIES 1 Decongestant/ Product Cough ...
The number of cough remedies available in the USA continues to multiply, but most products contain the same or similar ingredients in varying combinations. Most acute coughs do not require treatment with drugs, especially in children, and suppression of a productive cough may be harmful.
Med Lett Drugs Ther. 2001 Mar 19;43(1100):23-5 |  Show IntroductionHide Introduction

Valdecoxib (Bextra) - a New Cyclooxygenase-2 Inhibitor

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 2002  (Issue 1129)
, selective COX-2 inhibitors do not inhibit COX-1, which protects the gastric mucosa, and therefore should ...
Valdecoxib (Bextra - Pharmacia/Pfizer), a selective cyclooxygenase (COX-2) inhibitor similar to celecoxib (Celebrex) and rofecoxib (Vioxx), was recently approved by the FDA for treatment of osteoarthritis, rheumatoid arthritis and primary dysmenorrhea.
Med Lett Drugs Ther. 2002 Apr 29;44(1129):39-41 |  Show IntroductionHide Introduction

Alosetron (Lotronex) revisited

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2002  (Issue 1136)
, with an elimination half-life of about 1.5 hours. Plasma concentrations of alosetron are higher in women than in men ...
The FDA recently announced that it will permit reintroduction of alosetron hydrochloride (Lotronex - GlaxoSmithKline) for treatment of irritable bowel syndrome (IBS). The drug was previously withdrawn from the market because of severe gastrointestinal toxicity. The reintroduced drug will have a 50% lower starting dose, a narrower indication and some other marketing restrictions (www.fda.gov/cder/drug/infopage/lotronex/lotronex.htm).
Med Lett Drugs Ther. 2002 Aug 5;44(1136):67-8 |  Show IntroductionHide Introduction

Insulin-Sensitizing Drugs for Polycystic Ovary Syndrome

   
The Medical Letter on Drugs and Therapeutics • Apr 28, 2003  (Issue 1155)
from The Medical Letter 2002; 1:1), metformin (Glucophage, and others) decreases hepatic glucose output ...
Polycystic ovary syndrome (PCOS), an endocrine abnormality characterized by hyperandrogenism and anovulation, affects 5-10% of women of reproductive age in the US. It is often accompanied by obesity and insulin resistance. In recent years, antidiabetic drugs, although not approved for such use by the FDA, have been tried for treatment of this disorder. This review describes the effectiveness of metformin and the thiazolidinediones in women with PCOS. Also included is a dosage and cost table for some insulin-sensitizing drugs.
Med Lett Drugs Ther. 2003 Apr 28;45(1155):35-6 |  Show IntroductionHide Introduction

Sildenafil for Pulmonary Hypertension

   
The Medical Letter on Drugs and Therapeutics • Mar 01, 2004  (Issue 1177)
to standard treatment with diuretics and warfarin and, in 1 patient, a calcium-channel blocker, found ...
Several recent case reports suggest that oral sildenafil may be effective for treatment of pulmonary arterial hypertension (PAH). Sildenafil is currently marketed as Viagra for treatment of erectile dysfunction (Medical Letter 1998; 40:51).
Med Lett Drugs Ther. 2004 Mar 1;46(1177):18-9 |  Show IntroductionHide Introduction

Topical Sertaconazole (Ertaczo) -- Another Azole for Tinea Pedis

   
The Medical Letter on Drugs and Therapeutics • Jun 21, 2004  (Issue 1185)
alone. Two weeks after completion of therapy, 13.1% (13/99) and 27.2% (28/103) of patients treated ...
Sertaconazole nitrate (Ertaczo - OrthoNeutrogena), an imidazole antifungal similar to clotrimazole and miconazole, has been approved by the FDA as a 2% cream for topical treatment of interdigital tinea pedis infection. It has been available in Europe for many years.
Med Lett Drugs Ther. 2004 Jun 21;46(1185):50-2 |  Show IntroductionHide Introduction

L-Carnitine

   
The Medical Letter on Drugs and Therapeutics • Nov 22, 2004  (Issue 1196)
of primary carnitine deficiency since 1986. 1 Products containing levocarnitine and its synthetic ...
Carnitine is a naturally occurring amino acid derivative essential for transport of long-chain fatty acids into mitochondria. It is advertised on the Internet as a dietary supplement that can promote weight loss, increase energy, enhance athletic performance and slow aging. Levocarnitine (Carnitor - Sigma-Tau) has been FDA approved for oral and parenteral treatment of primary carnitine deficiency since 1986. Products containing levocarnitine and its synthetic derivative acetyl-L-carnitine are available as dietary supplements in the US.
Med Lett Drugs Ther. 2004 Nov 22;46(1196):95-6 |  Show IntroductionHide Introduction

Picaridin - A New Insect Repellent

   
The Medical Letter on Drugs and Therapeutics • Jun 06, 2005  (Issue 1210)
and allergic reactions to DEET have been uncommon, and serious adverse effects are rare. 1 Some patients ...
Picaridin (KBR 3023), which has been used as an insect repellent for years in Europe and Australia (Autan Repel, and others), is now available in the US in 7% solution as Cutter Advanced (Spectrum Brands). The US Centers for Disease Control and Prevention (CDC) is recommending it as an alternative to DEET.

Click here to view the free full article.
Med Lett Drugs Ther. 2005 Jun 6;47(1210):46-7 |  Show IntroductionHide Introduction

CYP3A and Drug Interactions

   
The Medical Letter on Drugs and Therapeutics • Jul 04, 2005  (Issue 1212)
and Drug Interactions Serious adverse interactions between drugs continue to be reported. 1 Many ...
Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in the metabolism of more than 50 percent of currently prescribed drugs.2 CYP3A4, which is more abundantly expressed than CYP3A5, accounts for most CYP3A activity in vivo.
Med Lett Drugs Ther. 2005 Jul 4;47(1212):54-5 |  Show IntroductionHide Introduction

VariZIG for Prophylaxis After Exposure to Varicella

   
The Medical Letter on Drugs and Therapeutics • Aug 14, 2006  (Issue 1241)
. Among patients who developed varicella, those treated within 1-4 days of exposure had milder symptoms ...
The US manufacturer of varicella zoster immune globulin (VZIG; Massachusetts Public Health Biologic Laboratories, Boston, MA) recently discontinued its production. A Canadian formulation, VariZIG (Varicella Zoster Immune Globulin [Human] - Cangene Corporation, Winnipeg) is now available in the US under an investigational new drug application expanded access protocol.
Med Lett Drugs Ther. 2006 Aug 14;48(1241):69-70 |  Show IntroductionHide Introduction